Gilead Sciences, Inc. (GILD) Presents at Baird 2022 Global Healthcare Conference (Transcript)Seeking Alpha • 09/14/22
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/13/22
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education EquityBusiness Wire • 09/13/22
7 Surprising Stocks With Fat Dividends That Offer Some Very Solid Inflation Protection24/7 Wall Street • 09/13/22
Gilead Sciences, Inc. (GILD) Presents at 2022 Wells Fargo Healthcare Conference - (Transcript)Seeking Alpha • 09/08/22
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 StudyBusiness Wire • 09/07/22
Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)Business Wire • 09/06/22
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 StatusBusiness Wire • 09/04/22
Gilead (GILD) Up 1.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/01/22
8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends24/7 Wall Street • 08/30/22
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022Business Wire • 08/29/22